title: [Evaluation of the organization of pre and post transfusion screening of viral infection markers in blood recipients in France in 2001].
abstract: In France, data collection related to blood recipient's viral infectious disease markers pre and post-transfusion is a legal requirement for hospitals. Our study aimed to evaluate the actual modalities of this extensive screening in 2001, six years after the Ministry of health issued recommendations. A questionnaire was sent to the haemovigilance correspondents in hospitals having transfused labile blood products (LBP) in 2001. A total of 1463 hospitals having transfused 85% of LBP in France responded. 82.4% of hospitals have written guidelines for pre-transfusion screening of viral markers, mainly for HIV and hepatitis C. A frozen repository storage is held by 23.9% of hospitals with storage durations between 1 to 40 years. 84% of hospitals have written guidelines for post-transfusion screening. The test prescriptions are mostly done by physicians from clinical services and they include in more than 80% of cases, HIV and HCV markers. Only 12% of hospitals recontact the patient in case of a no show. Even though 77.5% of responding hospitals have labile blood products recipients follow up processes, their effectiveness remains quite low, only 16% of recipients having test results available at the hospital.
authors.affiliation: DRASS Auvergne, Clermont-Ferrand, France. Pierre.fressy@sante.gouv.fr
authors.forename: P
authors.initials: P
authors.lastname: Fressy
authors.forename: G
authors.initials: G
authors.lastname: Daurat
authors.forename: N
authors.initials: N
authors.lastname: Duedari
authors.forename: G
authors.initials: G
authors.lastname: Le Blanc
authors.forename: D
authors.initials: D
authors.lastname: Taverne
authors.forename: N
authors.initials: N
authors.lastname: Ounnoughène
authors.forename: J
authors.initials: J
authors.lastname: Pillonel
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers; D001771:Blood Banks / Q000458:organization & administration* / Q000706:statistics & numerical data; D001793:Blood Preservation; D001803:Blood Transfusion / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data; D015925:Cryopreservation; D003625:Data Collection; D005500:Follow-Up Studies; D005602:France; D019983:Guideline Adherence; D017408:Guidelines as Topic; D015483:HIV Antibodies / Q000097:blood; D018937:Hepatitis C Antibodies / Q000097:blood; D006739:Hospital Administration; D006801:Humans; D008403:Mass Screening / Q000331:legislation & jurisprudence / Q000458:organization & administration* / Q000706:statistics & numerical data; D016134:Organizational Policy; D015397:Program Evaluation; D014777:Virus Diseases / Q000175:diagnosis*
chemical_list: D000914:Antibodies, Viral; D015415:Biomarkers; D015483:HIV Antibodies; D018937:Hepatitis C Antibodies; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase